Summary: H.Res.161 — 113th Congress (2013-2014)All Information (Except Text)

There is one summary for H.Res.161. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (04/15/2013)

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.